Gyre Therapeutics, Inc. GYRE
Biotechnology: Pharmaceutical Preparations · IPO 2006 · data as of November 13, 2026
Gyre Therapeutics, Inc. (GYRE) is a healthcare company listed in the US with a market value of about $497M. In the twelve months to September 30, 2026 it had revenue of $110M and net income of -$25M, a net margin of -22.7%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 41% a year, a 5-year average ROIC of -29%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.
About Gyre Therapeutics
Gyre Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2006. Revenue went from $275000 in 2014 to $117M in 2025, growth of about 73.3% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 36% over three years (dilution for shareholders). It spends 12% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $110M | $117M | $106M | $113M | $102M | $7M | $21M | — | $6000 | $1M | — |
| Net income | -$25M | $10M | $18M | -$85M | $4M | -$88M | -$56M | -$55M | -$30M | -$22M | -$17M |
| Free cash flow | -$8M | -$180000 | -$6M | $17M | $6M | -$85M | — | -$44M | -$29M | -$20M | -$19M |
| EPS (diluted) | $-0.23 | $0.02 | $0.05 | $-1.41 | $0.03 | $-2.87 | $-2.93 | $-4.60 | $-2.68 | $-7.45 | $-21.75 |
| Net margin | -22.7% | 8.5% | 16.9% | -75.3% | 4.2% | -1198.3% | -268.5% | — | -500900.0% | -2118.0% | — |
| ROIC | — | 7.3% | 19.2% | — | 17.1% | -159.7% | -58.3% | -64.5% | -22.3% | -48.1% | -45.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $18.67, 333% above the current price; targets range from $18.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-0.28 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Gyre Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Gyre Therapeutics pay a dividend?
Not currently.
Is Gyre Therapeutics a good stock to buy?
We do not give buy or sell advice. Gyre Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.